Charles Duncan
Stock Analyst at Cantor Fitzgerald
(4.12)
# 400
Out of 4,826 analysts
226
Total ratings
41.55%
Success rate
15.28%
Average return
Main Sectors:
Stocks Rated by Charles Duncan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMPS COMPASS Pathways | Reiterates: Overweight | n/a | $4.05 | - | 6 | Mar 28, 2025 | |
| ACAD ACADIA Pharmaceuticals | Reiterates: Overweight | $28 | $15.18 | +84.45% | 21 | Feb 27, 2025 | |
| JAZZ Jazz Pharmaceuticals | Downgrades: Neutral | $140 → $150 | $118.21 | +26.89% | 6 | Feb 26, 2025 | |
| AXSM Axsome Therapeutics | Reiterates: Overweight | $153 | $116.65 | +31.17% | 22 | Feb 19, 2025 | |
| GHRS GH Research | Initiates: Overweight | $14 | $11.26 | +24.33% | 1 | Feb 13, 2025 | |
| DRUG Bright Minds Biosciences | Initiates: Overweight | n/a | $31.21 | - | 1 | Jan 10, 2025 | |
| BHVN Biohaven | Reiterates: Overweight | n/a | $22.60 | - | 17 | Dec 17, 2024 | |
| STOK Stoke Therapeutics | Reiterates: Overweight | n/a | $9.71 | - | 7 | Dec 10, 2024 | |
| HRMY Harmony Biosciences Holdings | Maintains: Overweight | $51 → $58 | $29.93 | +93.79% | 8 | Oct 30, 2024 | |
| ALKS Alkermes | Maintains: Overweight | $48 → $43 | $31.43 | +36.81% | 5 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $36.67 | - | 7 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $8.08 | - | 15 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $155 | $109.75 | +41.23% | 9 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $13.10 | - | 3 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $35 | $15.95 | +119.44% | 6 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $13 | $4.60 | +182.61% | 5 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $6.44 | - | 6 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.43 | - | 2 | Jul 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $6.57 | - | 3 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.47 | - | 3 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $34 | $24.29 | +39.98% | 9 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $52 → $50 | $33.65 | +48.59% | 3 | Oct 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $5 | $4.24 | +17.92% | 1 | Sep 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4 | $0.42 | +860.61% | 4 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4 | $1.26 | +218.73% | 4 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $58 | $37.47 | +54.79% | 3 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $110 | $1.14 | +9,549.12% | 4 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $80 | $2.91 | +2,649.14% | 5 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $1.14 | +163.16% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $16 → $11 | $8.91 | +23.46% | 2 | Dec 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $9 → $12 | $6.30 | +90.48% | 2 | Nov 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $146 → $168 | $6.29 | +2,570.91% | 6 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $2.30 | +769.57% | 1 | Feb 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $200 | $21.72 | +820.81% | 3 | Feb 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $8 → $4 | $0.30 | +1,224.50% | 3 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $24 | $1.60 | +1,400.00% | 1 | Oct 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $372 → $144 | $1.86 | +7,662.80% | 6 | Sep 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $3 → $4 | $1.42 | +181.69% | 2 | Jun 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $35 → $39 | $60.62 | -35.66% | 4 | May 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $14 → $15 | $73.94 | -79.71% | 4 | Feb 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $0.72 | - | 3 | Nov 15, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $5.42 | +3,221.03% | 1 | Oct 9, 2017 |
COMPASS Pathways
Mar 28, 2025
Reiterates: Overweight
Price Target: n/a
Current: $4.05
Upside: -
ACADIA Pharmaceuticals
Feb 27, 2025
Reiterates: Overweight
Price Target: $28
Current: $15.18
Upside: +84.45%
Jazz Pharmaceuticals
Feb 26, 2025
Downgrades: Neutral
Price Target: $140 → $150
Current: $118.21
Upside: +26.89%
Axsome Therapeutics
Feb 19, 2025
Reiterates: Overweight
Price Target: $153
Current: $116.65
Upside: +31.17%
GH Research
Feb 13, 2025
Initiates: Overweight
Price Target: $14
Current: $11.26
Upside: +24.33%
Bright Minds Biosciences
Jan 10, 2025
Initiates: Overweight
Price Target: n/a
Current: $31.21
Upside: -
Biohaven
Dec 17, 2024
Reiterates: Overweight
Price Target: n/a
Current: $22.60
Upside: -
Stoke Therapeutics
Dec 10, 2024
Reiterates: Overweight
Price Target: n/a
Current: $9.71
Upside: -
Harmony Biosciences Holdings
Oct 30, 2024
Maintains: Overweight
Price Target: $51 → $58
Current: $29.93
Upside: +93.79%
Alkermes
Oct 25, 2024
Maintains: Overweight
Price Target: $48 → $43
Current: $31.43
Upside: +36.81%
Oct 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $36.67
Upside: -
Sep 30, 2024
Reiterates: Overweight
Price Target: n/a
Current: $8.08
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $155
Current: $109.75
Upside: +41.23%
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $13.10
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: $35
Current: $15.95
Upside: +119.44%
Aug 1, 2024
Maintains: Overweight
Price Target: $11 → $13
Current: $4.60
Upside: +182.61%
Jul 31, 2024
Reiterates: Overweight
Price Target: n/a
Current: $6.44
Upside: -
Jul 30, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.43
Upside: -
Jun 21, 2024
Reiterates: Overweight
Price Target: n/a
Current: $6.57
Upside: -
Jun 21, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.47
Upside: -
Mar 22, 2024
Reiterates: Overweight
Price Target: $34
Current: $24.29
Upside: +39.98%
Oct 24, 2023
Assumes: Overweight
Price Target: $52 → $50
Current: $33.65
Upside: +48.59%
Sep 22, 2023
Initiates: Overweight
Price Target: $5
Current: $4.24
Upside: +17.92%
Sep 7, 2023
Reiterates: Overweight
Price Target: $4
Current: $0.42
Upside: +860.61%
Aug 22, 2023
Reiterates: Overweight
Price Target: $4
Current: $1.26
Upside: +218.73%
Aug 22, 2023
Reiterates: Overweight
Price Target: $58
Current: $37.47
Upside: +54.79%
Aug 22, 2023
Reiterates: Overweight
Price Target: $110
Current: $1.14
Upside: +9,549.12%
Aug 16, 2023
Reiterates: Overweight
Price Target: $80
Current: $2.91
Upside: +2,649.14%
Aug 14, 2023
Reiterates: Overweight
Price Target: $3
Current: $1.14
Upside: +163.16%
Dec 6, 2022
Downgrades: Neutral
Price Target: $16 → $11
Current: $8.91
Upside: +23.46%
Nov 22, 2022
Upgrades: Overweight
Price Target: $9 → $12
Current: $6.30
Upside: +90.48%
Jun 8, 2022
Maintains: Overweight
Price Target: $146 → $168
Current: $6.29
Upside: +2,570.91%
Feb 18, 2022
Initiates: Overweight
Price Target: $20
Current: $2.30
Upside: +769.57%
Feb 18, 2022
Initiates: Overweight
Price Target: $200
Current: $21.72
Upside: +820.81%
Apr 20, 2021
Downgrades: Neutral
Price Target: $8 → $4
Current: $0.30
Upside: +1,224.50%
Oct 23, 2020
Initiates: Overweight
Price Target: $24
Current: $1.60
Upside: +1,400.00%
Sep 28, 2020
Downgrades: Neutral
Price Target: $372 → $144
Current: $1.86
Upside: +7,662.80%
Jun 1, 2020
Maintains: Overweight
Price Target: $3 → $4
Current: $1.42
Upside: +181.69%
May 4, 2020
Reiterates: Overweight
Price Target: $35 → $39
Current: $60.62
Upside: -35.66%
Feb 21, 2020
Reiterates: Neutral
Price Target: $14 → $15
Current: $73.94
Upside: -79.71%
Nov 15, 2017
Upgrades: Overweight
Price Target: n/a
Current: $0.72
Upside: -
Oct 9, 2017
Initiates: Overweight
Price Target: $180
Current: $5.42
Upside: +3,221.03%